CVS Health (NYSE:CVS) expects FY20 Adj. EPS of $7.14-$7.27 – same as previously expected, but at the midpoint shy of consensus forecasts for $7.23.
GAAP EPS guidance is trimmed from $5.59-$5.72 to $5.16-$5.29, thanks to charges on early payback of debt in Q3.
Cash flow from operations is still seen at $11B-$11.5B.
The company is presenting later today at the Morgan Stanley Global Healthcare Conference. Webcast here.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.